An expert summarizes real-world GA management lessons, highlighting personalized imaging-guided care and patient-centered strategies to maintain vision stability. Dr. Sambhara closes with ...

An expert outlines vision-preserving strategies for monocular high-risk GA, emphasizing early intervention and tailored therapy for safety and stability. Dr. Sambhara presents an 82-year-old monocular ...

A study reveals that lesion characteristics in geographic atrophy significantly influence growth rates, highlighting the need for targeted treatment strategies. The lesion characteristics of patients ...

In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Feistmann in an overview of office-based surgery, with actionable advice for retina specialists ...

AAO 2025: The safety and efficacy of oral gildeuretinol in participants with intermediate-stage Stargardt disease ...

Charles Miller, MD, PhD, on DME research and the initiation of the phase 2b/3 BRUNELLO trial ...

In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr Feistmann in an overview of office-based surgery, with actionable advice for retina specialists ...

Dr. Gonzalez shares 126-week topline results from the REMAIN study, assessing optogenetic therapy MCO-010 (Nanoscope Therapeutics). Ahead of the Clinical Trials at the Summit (CTS) meeting in Las ...

Although my practice is primarily an anterior segment practice, the care of patients with age-related macular degeneration (AMD) is something I have always followed closely. AMD is the leading cause ...

Aviceda Therapeutics has completed enrollment of the phase 2b trial of the SIGLEC Study. The study will assess the safety and efficacy of AVD-104, the company’s formulation designed to treat ...

Two FDA-approved geographic atrophy treatments show significant patient dropout, with 45% discontinuation by 18 months, driven by baseline vision, CNV, and lack of immediate visual improvement. In a ...

MCO-010 demonstrated a statistically significant improvement of best-corrected visual acuity (BCVA) at week 52. The 2-year Phase 2b RESTORE trial has achieved its primary and key secondary endpoints ...